Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

We sought to investigate the clinical profile(s) associated with the discontinuation of lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable hepatocellular carcinoma (HCC). This retrospective study enrolled 177 patients with HCC treated with LEN. Independent factors as...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimose, Shigeo, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Okamura, Shusuke, Nakano, Masahito, Suga, Hideya, Kuromatsu, Ryoko, Yamaguchi, Taizo, Kawaguchi, Takumi, Tanaka, Masatoshi, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408786/
https://www.ncbi.nlm.nih.gov/pubmed/32664489
http://dx.doi.org/10.3390/cancers12071867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408786/
https://www.ncbi.nlm.nih.gov/pubmed/32664489
http://dx.doi.org/10.3390/cancers12071867

Ejemplares similares